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Hepatitis B virus core promoter mutations G1613A and C1653T are significantly 
associated with hepatocellular carcinoma in genotype C HBV-infected patients 
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Accession numbers of full genome sequences of hepatitis B virus in this manuscript. 
HCC group 1 
[DDBJ: AB670237, AB670238, AB670239, AB670240, AB670241, AB670242, 
AB670243, AB670244, AB670245, AB670246, AB670247, AB670248, AB670249, 
AB670250, AB670251, AB670252, AB670253, AB670254, AB670255, AB670256, 
AB670257, AB670258, AB670259, AB670260, AB670261, AB670262, AB670263, 
AB670264, AB670265, AB670266, AB670267, AB670268, AB670269, AB670270, 
AB670271, AB670272, AB670273] 
 
non-HCC group 1 
 [DDBJ: AB670274, AB670275, AB670276, AB670277, AB670278, AB670279, 
AB670280, AB670281, AB670282, AB670283, AB670284, AB670285, AB670286, 
AB670287, AB670288, AB670289, AB670290, AB670291, AB670292, AB670293, 
AB670294, AB670295, AB670296, AB670297, AB670298, AB670299, AB670300, 
AB670301, AB670302, AB670303, AB670304, AB670305, AB670306, AB670307, 
AB670308, AB670309, AB670310, AB670311]
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                Abstract 
Background: Hepatitis B virus (HBV) is a major cause of hepatocarcinogenesis.  
To identify mutations relevant to hepatocellular carcinoma (HCC) development, we 
compared the full genome sequences of HBV from the sera of patients with and 
without HCC. Methods: We compared the full genome sequences of HBV isolates 
from 37 HCC patients (HCC group 1) and 38 patients without HCC (non-HCC group 
1). We also investigated part of the core promoter region sequences from 40 HCC 
patients (HCC group 2) and 68 patients without HCC. Of the 68 patients who initially 
did not have HCC, 52 patients remained HCC-free during the follow-up period 
(non-HCC group 2), and 16 patients eventually developed HCC (pre-HCC group 2). 
Serum samples collected from patients were subjected to PCR, and the HBV DNA 
was directly sequenced. Results: All patients had genotype C. A comparison of the 
nucleotide sequences of the HBV genome between HCC group 1 and non-HCC group 
1 revealed that the prevalence of G1613A and C1653T mutations in the core 
promoter region was significantly higher in the HCC group. These mutations tended 
to occur simultaneously in HCC patients. Multivariate analysis with group 2 revealed 
that the presence of HCC was associated with aging and the double mutation. Future 
emergence of HCC was associated with aging and the presence of a single G1613A 
mutation. Conclusions: G1613A and C1653T double mutations were frequently 
found in patients with HCC. A single G1613A mutation was associated with future 
emergence of HCC. These mutations may serve as useful markers in predicting HCC 
development. 
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Background 
Approximately 2 billion people worldwide have been infected with the hepatitis B 
virus (HBV). Of these, 350 to 400 million are chronic carriers of the virus [1, 2]. The 
clinical state of HBV infection is variable, ranging from acute hepatitis to various 
forms of chronic liver disease, such as chronic hepatitis, cirrhosis and hepatocellular 
carcinoma (HCC) [1]. 
Chronic HBV infection is a risk factor for HCC. Chronic inflammation and liver 
fibrosis caused by chronic HBV infection contributes to the occurrence of HCC [1]. 
However, in addition to these host factors, HBV itself has a direct role in the 
development of HCC [3, 4]. A significant proportion of HBV-related HCCs arise in 
otherwise normal livers [5, 6], and animal models transfected with this virus genome 
develop HCC; these observations confirm the oncogenic potential of HBV in the liver 
[3, 7]. Although a considerable amount of research has been conducted, the molecular 
basis of HBV-related hepatocarcinogenesis remains unknown [8, 9]. 
If HBV were directly oncogenic, variations in HBV could account for some of the 
heterogeneity in the clinical course of HCC development. Several studies have 
examined mutations within the HBV genome that may be associated with HCC. 
Genotypic diversity is related to differences in clinical and virological characteristics. 
For example, genotype C infected patients have more severe chronic liver disease, 
including cirrhosis and HCC [5, 10]. As for deletions and point mutations, which are 
more subtle genetic variations than genotype, previous studies have found some clues, 
such as codon 38 in X gene, A1762T/G1764A basal core promoter (BCP) mutation, 
and deletion of pre-S and X protein [11-13], but definitive conclusions have not yet 
been made. 
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Bias might be created by studying a limited number of patients, a limited section of 
the HBV-DNA sequence, and patients with different genotypes of HBV. Therefore, 
whole sequences of HBV-DNA from a genetically similar cohort of patients infected 
with the same HBV genotype might reduce viral genotypic and host genetic biases. In 
the present study, we investigated whole genome sequences of circulating HBV-DNA 
from the sera of HCC patients who were infected with HBV genotype C in the 
western part of Japan. 
 
Methods 
Patients 
Between 1988 and 2004, a total of 575 patients in our hospital were diagnosed as 
having HBV-related chronic liver diseases, and 138 of these patients developed HCC. 
Seventy-five patients were diagnosed with HCC at their first visit, and 63 patients 
were diagnosed with HCC during the subsequent follow-up period. The patient age 
range was from 29 to 75 years old, and there were 27 women and 111 men. 
We excluded patients who were presumed to have acute hepatitis B based on their 
sexual history, intravenous drug use or exposure to blood products, serological 
markers including high IgM-HBc antibody positivity and imaging findings showing 
no chronic liver disease with ultrasonography or computed tomography. Patients who 
had a history of alcoholism or other causes of hepatitis, such as autoimmune hepatitis, 
primary biliary cirrhosis, and Wilson’s disease were also excluded. We also excluded 
patients with a very low viral load due to our inability to extract HBV DNA from 
their serum. In total, we studied 217 serum samples from 183 patients with chronic 
HBV. Informed consent was obtained from each participant. The study was approved 
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by the ethics committee of Okayama University Hospital. 
Diagnosis of HCC was based on positive findings on ultrasonography, computed 
tomography and/or angiography. 
Design of the study 
 The overall study consisted of the following: (1) a matched case-control study was 
designed to find HBV mutations (from the entire HBV genome) significantly 
associated with HCC; (2) an unmatched case-control study was designed to validate 
the mutations associated with HCC; and (3) a nested case-control study in a cohort 
designed to see if the mutations found in the previous two case-control studies at 
baseline can predict the occurrence of HCC in patients with chronic hepatitis B.   
Isolates used for complete genome sequencing 
Complete viral genome sequencing was performed on viral DNA isolated from the 
sera of 37 patients who had HCC (HCC group 1) and 38 patients who did not have 
HCC or develop HCC during the follow-up period (non-HCC group 1). The mean 
follow-up period was 8.1 years. Serum samples from patients in non-HCC group 1 
were collected at their first visit. The ages and sex of non-HCC group 1 patients were 
matched with HCC group 1 patients. The patients from HCC group 1 and non-HCC 
group 1 had an HBV titer that was sufficient to extract enough DNA to determine the 
entire nucleotide sequence of the HBV genome. Patients did not have on 
nucleos(t)ide analogue treatment at the time of serum correction to extract enough 
DNA for sequencing. Liver histology was available for only 12 patients in non-HCC 
group 1 and was not used for statistical analysis. Three patients had stage 1 fibrosis; 6 
patients had stage 2 fibrosis; and 3 patients had stage 3 fibrosis.  
The characteristics of these patients are shown in Table 1. We could not calculate the 
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MELD (Model for End-Stage Liver Disease) score as a liver function marker because 
prothrombin time data for many patients were unavailable. We compared the 
sequences of the entire HBV genome between the two groups. 
 
Isolates used for core promoter sequences 
To define the reliability of correlations between core promoter mutations and 
hepatocarcinogenesis drawn by the whole genome analysis, we sequenced a small 
part of the core promoter region of an additional 108 isolates. Forty isolates were 
obtained from the HCC patients (HCC group 2), and 68 isolates were from the 
patients without HCC at their first visit. Of these 68 patients, 16 patients who 
developed HCC during the follow-up period were defined as pre-HCC group 2, and 
52 patients who did not develop HCC were labeled as non-HCC group 2.  
The mean follow-up period was 5.8 years for the non-HCC group 2 and 9.5 years for 
the pre-HCC group 2. 
Extraction and amplification of serum HBV DNA 
Serum samples were stored at -30°C until use. Nucleic acids were extracted from 200 
µL of serum using a commercially available kit (QIAamp DNA Blood Mini Kit; 
Qiagen Inc., Valencia, CA). 
To obtain a full-length HBV DNA sequence from the nucleic acids, we performed 
nested PCR to amplify two overlapping fragments with a PfuTurbo polymerase kit 
(Stratagene, La Jolla, CA). The PCR primer sequences and the relative positions of 
these PCR fragments on the genetic map of HBV DNA are shown in Table 2. 
  For sequencing a small part of the core promoter region, we performed PCR using 
5F/5R primers 
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Nucleotide sequencing of PCR products 
PCR products were sequenced directly by the dideoxy termination method using the 
Big Dye Terminator cycle sequencing Ready Reaction Kit ver. 3.1 (Applied 
Biosystems, Foster City, CA) with modifications and an automatic sequencer (ABI 
PRISM 3100 Genetic Analyser; Applied Biosystems). PCR products were sequenced 
in forward and reverse directions. Sequence alignment was performed by using the 
multiple-alignment algorithm in MegAlign (DNASTAR, Windows version 5.06, WI). 
Statistics 
SAS software (Version 6, SAS Institute Inc., NC) was used to conduct the statistical 
analysis. Continuous data were expressed as mean ± SD and were analyzed with 
one-way ANOVA for normally distributed data and with the Kruskal-Wallis test for 
other data. Categorical data were analyzed with Pearson’s Chi-square test. If a 
statistical difference was found, we compared the groups by using a Chi-square test 
with Bonferroni’s correction. Logistic regression analysis was used to assess the 
likelihood of a nucleotide change due to the influence of various factors related to the 
risk of HCC development. Cumulative HCC incidence curves were determined using 
the Kaplan-Meier method and the differences between groups were assessed with the 
log-rank test. Cox proportional hazard regression analysis was used to identify 
significant factors that influence future HCC development.  
 
Results 
Genotyping 
Phylogenetic trees that were constructed using the neighbor-joining method revealed 
that all patients in our study had genotype C and subgenotype C2. 
 9 
 
Analysis of full sequences 
To identify mutations associated with hepatocarcinogenesis, we studied the complete 
nucleotide sequences of the HBV genome isolated from the sera of patients who had 
HCC (HCC group 1; [DDBJ: AB670237-AB670273]) and who had not developed 
HCC (non-HCC group 1; [DDBJ: AB670274-AB670311]). 
Several deletions were found in the HBV genome. Most deletions were located in the 
pre-S and X regions. However, there were no significant differences between HCC 
group 1 (2 patients with pre-S1 deletions, 1 patient with pre-S2 deletion) and 
non-HCC group 1 (2 patients with pre-S1 deletions, 3 patients with BCP/X 
deletions). 
To identify point mutations relevant to HCC, we compared each nucleotide of the 
whole sequences of the HBV genome between HCC group 1 and non-HCC group 1. 
Of all 3215 base pairs, only two nucleotides showed significant differences between 
HCC group 1 and non-HCC group 1 (Table 3). The two mutations were both located 
in the core promoter region. A G-to-A mutation at nucleotide 1613 occurred in 38% 
of HCC group 1 and 10% of non-HCC group 1 (p<0.008). A C-to-T mutation at 
nucleotide 1653 occurred in 45% of HCC group 1 and 19% of non-HCC group 1 
(p<0.05).  
The A1762T/G1764A BCP mutation rate was not different between HCC group 1 and 
non-HCC group 1 (75% vs. 72%). However, the BCP mutation was frequently found 
in conjunction with the G1613A mutation or the C1653T mutation. The odds ratio of 
the BCP mutation was 8.2 in the G1613A mutant and 4.62 in the C1653T mutant as 
compared to wild type (p<0.05). 
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Comparison of sequences in the core promoter region 
We suspected that the two mutations in the core promoter region were relevant to 
hepatocarcinogenesis. To determine the reliability of this result, we examined an 
additional 108 isolates to sequence a part of the core promoter region. The results of 
the core promoter region analysis were similar to our results from the whole genome 
sequencing. The rate of the G1613A and C1653T mutations were significantly higher 
in patients with HCC (Table 4). The rate of the G1613A and C1653T mutations was 
50% and 50% in HCC group 2, while each of these mutations was found in only 12% 
of the non-HCC group 2 (p<0.05). Statistical analysis revealed that G1613A and 
C1653T mutations were dependent on each other. The rate of the G1613A mutation 
was significantly higher in isolates with the C1653T mutation as compared to isolates 
without the C1653T mutation (65% vs. 34 %, p<0.05) and vice versa (65% vs. 34%, 
p<0.05). The combination of these mutations was significant in HCC group 2. The 
G1613A and/or the C1653T mutations were found at a significantly lower frequency 
in the non-HCC group 2. Clinical parameters, such as aging, albumin level and 
platelet count, showed a tendency to be related to HCC group 2 (Table 1), indicating 
that these mutations might occur with liver fibrosis progression. However, the double 
mutation rate was high only in HCC group 2 (Table 4). 
 
Patient characteristics and the 1613/1653 mutations 
We determined whether the positivity of the HBe antigen (HBeAg) was related to the 
mutations. The G1613A mutation was found in 32% of HBeAg-positive patients and 
24% of HBeAg-negative patients (N.S. data not shown). The C1653T mutation was 
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found in 27% of HBeAg-positive patients and in 31% of HBeAg-negative patients 
(N.S.). The double mutation rate was not different with positivity of the HBeAg (14% 
HBeAg-positive vs. 18% HBeAg-negative). The positive rate of HBeAg did not 
correlate with these mutations (Table 5). The mutations tended to occur with aging in 
HCC group 2, although this tendency was not statistically significant. The ratio of 
mutation was not different with aging in non-HCC group 2. 
 
Multivariate analysis 
To evaluate the effect of the mutations on the development of HCC, multiple logistic 
regression analysis was performed with the clinical features and the G1613A and 
C1653T mutations (Table 6). 
In our first analysis, we used HCC group 2 and non-HCC group 2 to evaluate the 
effect of the double mutation on the presence of HCC. The following characteristics, 
which were proven to be statistically significant with univariate analysis, were used 
for multiple logistic regression analysis: age ≥45, Plt (×104/μl) ≤14, ALT (≥70), and 
the presence of G1613A and C1653T. The presence of HCC was associated with the 
double mutation and increased age. 
In our second analysis, we used non-HCC group 2 and the pre-HCC group 2 to 
evaluate the effect of the mutation on the later occurrence of HCC. The following 
characteristics, which were proven to be statistically significant with univariate 
analysis, were used for multiple logistic regression analysis: age ≥45 years, male, and 
the G1613A mutation. The presence of the G1613A mutation was significantly higher 
in the group that later developed HCC. However, cox proportional hazard regression 
analysis showed only low platelet count to be the predictor of later HCC occurrence.  
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Discussion 
In the present study, we compared the whole HBV genome sequence of 37 HCC 
patients with 38 non-HCC patients. All patients were infected with genotype C 
viruses, and the most common mutations were G1613A and C1653T. Patients with 
both mutations were at a particularly high risk for the presence of HCC. The 
association between these mutations and hepatocellular carcinoma development was 
confirmed in an analysis of 183 subjects. An analysis of HCC development during the 
patient follow-up period revealed that the presence of G1613A and/or C1653T 
mutations was more prevalent in patients who developed HCC long afterward, as 
compared to the patients who never developed HCC. 
Several studies have revealed the relationship between mutations and 
hepatocarcinogenesis [9, 13-18]. Our hospital is located in the western side of Japan, 
where genotype C is endemic [19], population mobility is low and the ethnicity is 
homogeneous. The resulting similarities among study subjects support the reliability 
of our results.  
The risk for hepatocarcinogenesis is higher in genotype C HBV patients as compared 
with other genotypes [20]. In different genotypes, the effect of a single point mutation 
on the function of viral proteins could be different. Our results shed light on the risk 
of viral mutations on hepatocarcinogenesis in high-risk HBV genotype C 
(subgenotype C2)-infected patients. 
The G1613A and C1653T mutations are both located in the core promoter region [21]. 
Mutations in the core promoter region have clinical consequences to the host caused 
by changes in viral characteristics, such as transcription of the pregenomic and pre-C 
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RNAs.  
The nucleotide at position 1613 is located at the N-terminal end of the negative 
regulatory element, upstream of Enhancer II (ENII), which can repress the function of 
ENII [22]. Mutational analysis has shown that the sequence from 1612 to 1615 is 
responsible for the repression activity of the negative regulatory element [23]. The 
1613 mutation can result in the failure of the repression function of the negative 
regulatory element and in the proliferation of virus-related proteins that might induce 
hepatocarcinogenesis. Nucleotide 1613 is also located within overlapping open 
reading frames, the X gene at codon 80 (which results in a synonymous change in X 
protein) and polymerase gene, which contains the C-terminal side of the RNaseH 
domain (A to K change). 
The nucleotide at position 1653 is located in the core upstream regulatory sequence 
(CURS) region, which has a strong stimulatory effect on the basic core promoter 
independent of enhancer II [24]. CURS is divided into two regions, A (5’-half; 
nucleotides 1636-1703) and B (3’-half; nucleotides 1704-1743), which can 
independently stimulate BCP activity. The 1653 position is located in the box alpha 
domain that might change the stimulatory effect on BCP. Nucleotide 1653 is also 
located within the X gene at codon 94. X protein binds and affects several 
intracellular signal transduction pathways, cell cycle progression, and apoptosis 
regulation [25]. Codon 94 of X protein is included in area of several transcription 
factor binding sites, such as CREB, RPB5, TFIIB, XAP-1, C/EBPalpha, and XAP-3. 
Although this region does not directly bind p53 protein, it contains a p53-dependent 
transcriptional repression binding site that is necessary for negative regulation of a 
p53-induced viral-specific DNA enhancer [21, 26].  
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Several previous studies have reported the association of the mutations at 1613 or 
1653 with HCC development. In a Japanese study, Takahashi et al. found that 
G1613A and C1653T occurred in 38% and 40%, respectively, of 40 HCC patients 
[15]. However, their study did not include a non-HCC control group and did not 
analyze confounding host factors. Shinkai et al. reported that the combination of 
C1653T and/or V1753 mutations in addition to T1762/A1764 mutations was 
differentially associated with HCC in HBeAg-positive genotype C patients [27]. 
Although nucleotide 1613 was outside the range of their sequence analysis, their data 
were partially consistent with our observations. A recent study from China revealed 
that 1613 and 1653 mutations were included in mutations frequently detected in HCC 
patients; however, core region mutants A2189C and G2203W were independent risk 
factors for HCC [18]. A meta-analysis of 43 studies revealed that PreS mutation, 
C1653T, T1753V, and A1762T/G1764A were dominant in HCC [28]. PreS mutation 
in genotype C virus was more strongly associated with HCC than PreS mutation in 
genotype B virus. We could not find any significant differences of the PreS region. 
Our patient population had an average age of 38 years, which might be too young to 
accumulate such mutations or large deletions. 
Although there have been many reports of important mutations, a definite consensus 
regarding the significance of mutations in HCC development has not yet been 
reached. Several factors have made it difficult to reach a consensus. It is difficult to 
define non-HCC patients, and even when patients are HCC-free for several years, 
they may eventually develop HCC. Moreover, there are many confounding factors in 
hepatocarcinogenesis, such as patient age, HBeAg status, and liver cirrhosis. Another 
limitation of previous studies was the relatively small number of subjects (40 or less) 
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and the mixture of several HBV genotypes. We compared 37 HCC patients with 38 
non-HCC patients. Our multivariate analysis with 40 HCC group 2 patients and 52 
non-HCC group 2 patients revealed that HCC was associated with increased age and 
the presence of the 1613/1653 double mutation. The mutations might increase with 
aging; however, the age matched case-control study revealed the significance of the 
mutations. The future emergence of HCC is correlated with only G1613A mutation, 
while the double mutation was associated with the presence of HCC. Acquiring the 
double mutation might affect the carcinogenesis. Further studies regarding the 
functional changes in HBV DNA induced by this combination of mutations are 
clearly needed. 
The BCP or precore mutations have been reported to be associated with patient 
characteristics, such as age, sex, HBeAg-positive status and the clinical course as 
fulminant hepatitis and liver cirrhosis, especially in genotype C [21, 29-31]. Since 
these mutations are frequently found among patients without HCC, the use of these 
mutations as a marker for HCC surveillance may not be cost effective [32]. In the 
present study, the BCP mutation was found in 75% of HCC patients and 72% of 
non-HCC patients, which is not statistically different. Since our subjects all had 
genotype C virus, this high frequent BCP mutation rate is appropriate. In genotype C 
virus infected patients, the BCP mutation is reported to accumulate as aging and 
associated with an increased risk of HCC, however, when the BCP mutation 
coexisted with precore mutation, the risk of HCC have decreased[33, 34]. Probably 
the BCP mutation needs combination of other several mutations to induce 
hepatocarcinogenesis. Our patients’ ages were 37 for HCC group 1 and 38 for 
non-HCC group 1 suggesting young enough not to accumulate these mutations. The 
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G1613A and C1653T mutations were not associated with sex or HBeAg-positive 
status. Our follow-up analysis revealed that the G1613A mutation was prevalent in 
patients who would later develop HCC. This result suggests that these mutations 
could predict HCC development. In our study, the mean follow-up period was 8.1 
years. Although this amount of time is not a measure of the whole lifetime of patients 
with chronic HBV infection, it is long enough to evaluate the incubation period of 
HCC.  
The PreS mutation in genotype C virus is more strongly associated with HCC than 
the PreS mutations in genotype B virus[35]. Deletions of preS2 or X have been 
reported to be associated with HCC development [33, 34]. However, in our study, 
deletions in the pre-S1/S2 gene were observed similarly in the HCC group and 
non-HCC group. Our patient population might be too young to accumulate such 
mutations or large deletions as BCP were. Pre-S2 variants have been revealed that 
could not express pre-S2 and normal sized pre-S1 proteins, resulting in the retention 
of HBs antigen (HBsAg) in the cytoplasm with a subsequent decrease in HBsAg and 
HBV-DNA in serum[34]. In the present study, we included only the subjects with 
high viral load that was sufficient to analyze the whole genome sequences. This may 
be one additional reason why we did not frequently find pre-S2 variants, which 
should be found in patients with a low viral load.  
The predictive value of the mutation results is relatively high. This might be the 
results of small number of the cohort as the 95% confidence interval is wide. For 
more precise analysis, we need more number of the patients. We had attempted to add 
more samples for sequencing. However, recently diagnosed patients are almost all 
treated with nucleos(t)ide analogues. As a result, the viral DNA levels are very low, 
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and it is difficult to add more samples. 
 Conclusions 
We analyzed the full-length sequence of peripheral blood serum HBV DNA of HCC 
and non-HCC patients. Two mutations in the core promoter region, G1613A and 
C1653T, were associated with hepatocarcinogenesis. A single G1613A mutation was 
associated with future emergence of HCC that could be a marker for predicting HCC 
development.  
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Tables 
Table 1  Clinical parameters of the subjects used for HBV sequencing 
 
whole HBV sequencing    
 HCC group 1 non-HCC group 1  
  (n=37) (n=38)  
Age (Years) 37±10.0 38±11.6  
Sex:Male 29 (78%) 28 (73%)  
HBV-DNA (log/ml) 5.5±1.1 5.2±0.9  
HBeAg positive 20 (54%) 20 (52%)  
Platelet (x104/μl) 11.4±5.3 16.4±6.0  
Total Bilirubin (mg/dl) 1.3±1.1 1.6±1.97  
Albumin (g/dl) 3.58±0.8 4.0±0.44  
    
core promoter 
sequencing    
  HCC group 2 non-HCC group 2 pre-HCC group 2 
  (n=40) (n=52) (n=16) 
Age (Years) 54±13.1 38±11.4*# 48±10.2 
Sex:Male 78%  83%  94% * 
HBV-DNA (log/ml) 5.76±2.04 7.23±1.37* 6.42±1.66 
HBeAg positive 55%  75%  79%  
Platelet (x104/μl) 12.1±6.39 17.1±7.15* 15.0±6.59 
Total Bilirubin (mg/dl) 1.32±1.13 1.29±2.07 2.55±6.66 
Albumin (g/dl) 3.58±0.84 4.10±0.51* 3.84±0.57 
    
*p<0.05 vs. HCC group 2, #p<0.05 vs. pre-HCC group 2 
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Table 2  Primers used sequencing      
              
Primer Nucleotide Sequence (5' 3')   Position    
HB1F AAGCTCTGCTAGATCCCAGAGT  18-39 Sense 
HB1R GAAACATAGAGGTGCCTTGAGCAG  557-534 Antisense 
HB2F TGCTGCTATGCCTCATCTTC   414-433 Sense 
HB2R CATACTTTCCAATCAATAGG   989-970 Antisense 
HB3F GCCAAGTCTGTACAACATCTTGAG  760-783 Sense 
HB3R AGTTGGCGAGAAAGTGAAAGCCTG  1107-1084 Antisense 
HB4F CCTATTGATTGGAAAGTATGTCA  970-992 Sense 
HB4R CGGGACGTAGACAAAGGACGT  1434-1414 Antisense 
HB5F CTCTGCCGATCCATACTGCGGAA  1256-1278 Sense 
HB5R TTAACCTAATCTCCTCCCCCA  1761-1741 Antisense 
HB6F TTGTYTACGTCCCGTCGGCG   1421-1440 Sense 
HB6R AACAGACCAATTTATGCCTA   1803-1784 Antisense 
HB7F GAGACCACCGTGAACGCCCA   1611-1630 Sense 
HB7R CCTGAGTGCTGTATGGTGAGG   2072-2048 Antisense 
HB8F TTCACCTCTGCCTAATCATC   1824-1843 Sense 
HB8R ATAGGGGCATTTGGTGGTCT   2314-2278 Antisense 
HB9F TCAGGCAACTATTGTGGTTTCA  2190-2211 Sense 
HB9R GGATAGAACCTAGCAGGCAT   2654-2635 Antisense 
HB10F CGCAGAAGATCTCAATCTCGG  2417-2437 Sense 
HB10R GGGTTGAAGTCCCAATCTGGATT  2987-2965 Antisense 
HB11F GGGTCACCATATTCTTGGGAA  2814-2834 Sense 
HB11R GAACTGGAGCCACCAGCAGG   75-56 Antisense 
HB12F GTGGAGCCCTCAGGCTCAGG   3075-3094 Sense 
HB12R CGAGTCTAGACTCTGTGGTA    256-237 Antisense 
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Table 3  The prevalence of mutations in the samples     
      
      
 Mutation frequency 
Locations in open reading 
frames 
  HCC group 1 non-HCC group1 Pol X C S 
G162A 42% 26% 357   177 
A306G 9% 0% 405   225 
A456G 10% 0% 455   275 
C928T 37% 40% 613    
C955T 11% 8% 622    
A1032C 0% 7% 647    
A1053G 33% 19% 654    
A1126C 36% 41% 679    
T1134C 36% 35% 681    
T1323C 9% 16% 744    
G1356A 7% 0% 755    
C1485T 25% 27% 798 38   
G1499A 37% 34% 803 42   
G1511A 29% 23% 807 46   
G1613A 38% 10%* 841 80   
A1633G 5% 0%  87   
C1653T 45% 19%*  94   
G1727A 36% 51%  118   
A1762T 74% 77%  130   
G1764A 80% 84%  131   
G2080A 13% 14%   89  
C2444A 10% 0% 46  211  
A2574G 24% 14% 90    
C2586A 7% 0% 94    
A2696G 8% 0% 130    
G2783A 38% 33% 159    
C2919T 5% 0% 205   24 
C3026T 20% 16% 240   60 
T3098C 19% 2% 84     264 
  *p<0.05 vs. HCC group 1    
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Table 4   The frequency of G1613A and C1653T mutations 
    
  HCC group 2 non-HCC group 2 pre-HCC group 2 
  (n=40) (n=52) (n=16) 
mutation    
G1613A 50% 12%* # 38% * 
C1653T 50% 12%* 13% * 
G1613A and C1653T 35% 6%* 0%* 
G1613A and/or C1653T 65% 17%* #  50%  
    
*p<0.05 vs. HCC group 2,  #p<0.05 vs. pre-HCC group,   
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Table 5  Mutations and clinical findings   
       
HCC group 2 (n=40)     
Mutation 
(1613/1653) -/- +/- -/+ +/+ 
n 14  6  6  14  
HBeAg (positive) 40% 60% 50% 67% 
Sex (Male) 79% 83% 83% 71% 
Patient age 54.6±14.3- 43.3±6.7 57.8±18.3 57.8±9.5 
Non-HCC group 2 (n=52)    
Mutation 
(1613/1653) -/- +/- -/+ +/+ 
n 43  3  3 3 
HBeAg (positive) 78% 50% 33% 100% 
Sex (Male) 81% 100% 67% 100% 
Patient age 37.8±11.0 32.0±17.3 48.7±7.0 30.7±10.2 
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Table 6  Multivariate analyses for the development of HCC 
 
1.Factors associated with HCC presence  
 Multivariate analysis  
Factor Odds ratio 95% CI p value 
Age (≥45) 7.13 2.39-23.39 0.0004  
G1613A and C1653T 7.19 1.42-56.0 0.016  
2. Factors associated with future HCC emergence 
 Multivariate analysis  
Factor Odds ratio 95% CI p value 
Age (≥45) 4.89 1.41-18.69 0.010 
G1613A 4.73  1.11-21.69 0.035 
3. Factors associated with the occurrence of HCC by 
Multivariate Cox proportional hazard regression analysis 
Factor Odds ratio 95% CI p value 
Platelet (<14 x104/μl) 6.28 1.66-30.11 0.0065 
 
 
 
